MK-7622 is used as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for the symptomatic treatment of participants with mild to moderate Alzheimer's Disease (AD). Now MK-7622 is in phase II clinical trials by Merck.
Contact：Wuhan Sun-shine Bio-technologyCorporation Limited Add: Building C16, No.388Gaoxin 2Road, East Lake Hi-tech Development Zone, Wuhan 430200, China Tel: +86-27-65522452 QQ：1973737790 Web:http://www.sun-shinechem.com
| 
